NBIX
Price
$128.91
Change
+$0.68 (+0.53%)
Updated
Aug 1 closing price
Capitalization
13.72B
94 days until earnings call
NBY
Price
$0.59
Change
+$0.01 (+1.72%)
Updated
Aug 1 closing price
Capitalization
3.45M
Interact to see
Advertisement

NBIX vs NBY

Header iconNBIX vs NBY Comparison
Open Charts NBIX vs NBYBanner chart's image
Neurocrine Biosciences
Price$128.91
Change+$0.68 (+0.53%)
Volume$1.4M
Capitalization13.72B
NovaBay Pharmaceuticals
Price$0.59
Change+$0.01 (+1.72%)
Volume$30.89K
Capitalization3.45M
NBIX vs NBY Comparison Chart in %
Loading...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Exact Sciences Corp (NASDAQ:EXAS), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL).

Industry description

Few industries pique investor interest like the high-risk, high-reward biotechnology sector. It is not unusual for a biotech company’s stock to soar in value following the development of a successful product...even if it is just as likely that tens of millions of dollars in research will lead to nothing substantial. Biotech companies earn headlines for developing lifesaving and (potentially) massively lucrative treatments for illness, but the industry’s scope extends beyond healthcare to food and agriculture, industrial processing, and more. Any company producing technology that incorporates biological organisms falls within the sector. The search for the next big thing in biotech may come with risk, but investors have reason for optimism. Biotech products like DNA sequencing and gene therapy are experiencing increased demand and decreasing prices, while rising populations around the world mean demand for food and agricultural products resistant to environmental factors. Biotech’s biggest names include multinational corporations like Johnson & Johnson, Amgen, and Roche, who each sport market capitalizations in the hundreds of billions of dollars. With new government rules opening China as a market for new treatments, the biotech sector holds significant growth potential – and corresponding profitability for investors.

Market Cap

The average market capitalization across the biotechnology Theme is 7B. The market cap for tickers in the group ranges from 658 to 220.19B. TMO holds the highest valuation in this group at 220.19B. The lowest valued company is MTEM at 658.

High and low price notable news

The average weekly price growth across all stocks in the biotechnology Theme was 5%. For the same Theme, the average monthly price growth was 7%, and the average quarterly price growth was 20%. MRSN experienced the highest price growth at 2,039%, while ADAP experienced the biggest fall at -77%.

Volume

The average weekly volume growth across all stocks in the biotechnology Theme was -1%. For the same stocks of the Theme, the average monthly volume growth was 73% and the average quarterly volume growth was 201%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 76
Price Growth Rating: 56
SMR Rating: 88
Profit Risk Rating: 90
Seasonality Score: -20 (-100 ... +100)

Market Cap

The average market capitalization across the group is 6.86B. The market cap for tickers in the group ranges from 3.45M to 13.72B. NBIX holds the highest valuation in this group at 13.72B. The lowest valued company is NBY at 3.45M.

High and low price notable news

The average weekly price growth across all stocks in the group was -7%. For the same group, the average monthly price growth was -3%, and the average quarterly price growth was -13%. NBIX experienced the highest price growth at -2%, while NBY experienced the biggest fall at -12%.

Volume

The average weekly volume growth across all stocks in the group was 94%. For the same stocks of the group, the average monthly volume growth was 109% and the average quarterly volume growth was 94%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 41
P/E Growth Rating: 50
Price Growth Rating: 51
SMR Rating: 36
Profit Risk Rating: 99
Seasonality Score: -62 (-100 ... +100)
VS
NBIX vs. NBY commentary
Aug 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NBIX is a StrongBuy and NBY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 02, 2025
Stock price -- (NBIX: $128.91 vs. NBY: $0.59)
Brand notoriety: NBIX and NBY are both not notable
NBIX represents the Pharmaceuticals: Other, while NBY is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: NBIX: 151% vs. NBY: 86%
Market capitalization -- NBIX: $13.72B vs. NBY: $3.45M
NBIX [@Pharmaceuticals: Other] is valued at $13.72B. NBY’s [@Biotechnology] market capitalization is $3.45M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $213.98B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.87B. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NBIX’s FA Score shows that 0 FA rating(s) are green whileNBY’s FA Score has 2 green FA rating(s).

  • NBIX’s FA Score: 0 green, 5 red.
  • NBY’s FA Score: 2 green, 3 red.
According to our system of comparison, NBY is a better buy in the long-term than NBIX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NBIX’s TA Score shows that 4 TA indicator(s) are bullish while NBY’s TA Score has 4 bullish TA indicator(s).

  • NBIX’s TA Score: 4 bullish, 5 bearish.
  • NBY’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both NBIX and NBY are a bad buy in the short-term.

Price Growth

NBIX (@Pharmaceuticals: Other) experienced а -2.44% price change this week, while NBY (@Biotechnology) price change was -11.73% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.01%. For the same industry, the average monthly price growth was +5.21%, and the average quarterly price growth was +81.83%.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.14%. For the same industry, the average monthly price growth was +15.55%, and the average quarterly price growth was +36.18%.

Reported Earning Dates

NBIX is expected to report earnings on Nov 04, 2025.

NBY is expected to report earnings on May 15, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-2.01% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Biotechnology (+0.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBIX($13.7B) has a higher market cap than NBY($3.45M). NBIX has higher P/E ratio than NBY: NBIX (57.20) vs NBY (0.02). NBY YTD gains are higher at: -1.248 vs. NBIX (-5.560). NBIX has higher annual earnings (EBITDA): 358M vs. NBY (-6.8M). NBIX has more cash in the bank: 1.03B vs. NBY (8.47M). NBY has less debt than NBIX: NBY (1.13M) vs NBIX (428M). NBIX has higher revenues than NBY: NBIX (1.89B) vs NBY (9.78M).
NBIXNBYNBIX / NBY
Capitalization13.7B3.45M396,871%
EBITDA358M-6.8M-5,262%
Gain YTD-5.560-1.248446%
P/E Ratio57.200.02234,975%
Revenue1.89B9.78M19,293%
Total Cash1.03B8.47M12,188%
Total Debt428M1.13M38,044%
FUNDAMENTALS RATINGS
NBIX vs NBY: Fundamental Ratings
NBIX
NBY
OUTLOOK RATING
1..100
1658
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
13
Undervalued
PROFIT vs RISK RATING
1..100
98100
SMR RATING
1..100
6012
PRICE GROWTH RATING
1..100
4854
P/E GROWTH RATING
1..100
5050
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBY's Valuation (13) in the Biotechnology industry is somewhat better than the same rating for NBIX (70). This means that NBY’s stock grew somewhat faster than NBIX’s over the last 12 months.

NBIX's Profit vs Risk Rating (98) in the Biotechnology industry is in the same range as NBY (100). This means that NBIX’s stock grew similarly to NBY’s over the last 12 months.

NBY's SMR Rating (12) in the Biotechnology industry is somewhat better than the same rating for NBIX (60). This means that NBY’s stock grew somewhat faster than NBIX’s over the last 12 months.

NBIX's Price Growth Rating (48) in the Biotechnology industry is in the same range as NBY (54). This means that NBIX’s stock grew similarly to NBY’s over the last 12 months.

NBIX's P/E Growth Rating (50) in the Biotechnology industry is in the same range as NBY (50). This means that NBIX’s stock grew similarly to NBY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NBIXNBY
RSI
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
50%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
55%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 15 days ago
82%
Declines
ODDS (%)
Bearish Trend 12 days ago
61%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
YQQQ13.850.18
+1.33%
YieldMax Short N100 Option Inc Strgy ETF
PAB42.470.37
+0.89%
PGIM Active Aggregate Bond ETF
CMDY50.08-0.18
-0.37%
iShares Blmbrg Roll Sel Cmdty Strart ETF
AVIE59.51-0.27
-0.46%
Avantis Inflation Focused Equity ETF
IGRO76.08-0.70
-0.91%
iShares International Dividend Gr ETF

NBIX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NBIX has been loosely correlated with LFCR. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if NBIX jumps, then LFCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
+0.53%
LFCR - NBIX
34%
Loosely correlated
-0.14%
ELAN - NBIX
31%
Poorly correlated
+0.80%
EOLS - NBIX
31%
Poorly correlated
+2.12%
CGC - NBIX
30%
Poorly correlated
+1.94%
TLRY - NBIX
26%
Poorly correlated
-2.10%
More

NBY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been loosely correlated with PRTG. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if NBY jumps, then PRTG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
+2.15%
PRTG - NBY
38%
Loosely correlated
-9.06%
ALT - NBY
30%
Poorly correlated
-2.17%
ORMP - NBY
29%
Poorly correlated
-1.40%
IMMP - NBY
25%
Poorly correlated
-1.15%
PMN - NBY
25%
Poorly correlated
-0.60%
More